Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ORBOTECH LTD | ORBK | 10.86% |
| NOAH HOLDING | NOAH | 9.92% |
| SONIC FOUNDR | SOFO | 9.45% |
| VIPSHOP HOLD | VIPS | 9.20% |
| RENEWABLE EN | REGI | 8.98% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
U.S. health insurer Aetna Inc. ( AET - Analyst Report ) reported its third quarter 2012 earnings of $1.55 per share, way ahead of the Zacks Consensus Estimate of $1.34 per share. Earnings also increased 11% year over year.
The better-than-expected earnings of the company were the results of revenue growth, higher underwriting margins, increased membership coupled with lower operating costs.
Aetna’s total revenue for the reported quarter grew 6% year over year to $8.9 billion, led by higher Health Care premiums in each of the company’s Commercial, Medicare as well as Medicaid businesses. Reported revenue was in line with the Zacks Consensus Estimate.
Operating expenses were $1.64 billion, down 9.7% year over year. Operating expense ratio was 18.3 % compared with 20.0% in the prior-year quarter.
Pre-tax operating margin was 10.2 % for the reported quarter, down 50 basis points year over year.
Segment Performance
Aetna’s Health Care segment recorded revenues of $8.24 billion, up 5.9% year over year. Total premium increased 7.0% year over year to $7.2 billion, primarily attributable to an increase in Medicare premium and higher Commercial premium yields.
Total medical membership increased by 149,000 sequentially to 18.178 million following the acquisition of Genworth Financial's Medicare Supplement business.
The company’s Group Insurance revenues climbed 8.5% year over year to $530.8 million. The segment’s operating earnings plummeted 23% year over year to $29.3 million.
At Large Case Pensions, revenues declined 3.3% year over year to $123.9 million and operating earnings fell 16% year over year to $3.7 million.
2012 Guidance Update
Following the better-than-expected performance, Aetna raised its 2012 earnings expectation to $5.10 from the earlier guidance range of $5.00–$5.10 per share.
Our Take
Going forward, we expect Aetna to post favorable earnings. The company has made considerable investments in products and technology, with an intention to extend its core health business and also to capitalize on exciting new consumer and provider opportunities emerging in the marketplace.
Aetna's strong operating results and significant capital generation will allow it to make further investments. We expect the company to continue performing well in 2012 backed by the performance of the Medicaid and Medicare segments, fast growing health services segment and a strong balance sheet.
Last week, Aetna’s peer UnitedHealth Group Inc. ( UNH - Analyst Report ) reported its third quarter 2012 earnings of $1.50 per share, significantly ahead of the Zacks Consensus Estimate of $1.31 per share. Earnings also grew 9% year over year. Other peers Cigna Corp. ( CI - Analyst Report ) , WellPoint Inc. ( WLP - Analyst Report ) , Humana Inc. ( HUM - Analyst Report ) are expected to release their earnings soon.
Aetna currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. Considering the fundamentals, we are also maintaining our long-term Neutral recommendation on the shares
Read the full Analyst Report on WLP
Read the full Analyst Report on AET
Read the full Analyst Report on HUM
Read the full Analyst Report on CI
Read the full Analyst Report on UNH